Dental Care Clinics in Harvard, MA Accepting Medicare
7 Dental Care Clinics found. Showing 1 - 7
 Sai Smile Center Pllc Dentist Medicare: Not Enrolled in Medicare Practice Location: 325 Ayer Rd, Harvard, MA 01451 Phone: 978-772-6658 |
Dental Center Of Harvard Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 40 Massachusetts Ave, Harvard, MA 01451 Phone: 978-456-8737 |
M&m Dental, Llc Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 200 Ayer Rd Ste 101, Harvard, MA 01451 Phone: 978-456-0888 |
Care Smile Dental Dentist Medicare: Not Enrolled in Medicare Practice Location: 200 Ayer Rd, Ste A, Harvard, MA 01451 Phone: 978-456-0888 Fax: 978-456-0408 |
Harvard Dental Smile,pllc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 325 Ayer Rd Ste A110, Harvard, MA 01451 Phone: 978-772-6658 Fax: 978-772-2797 |
Geeta Puthalpet Dmd, Llc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 257 Ayer Rd, Harvard, MA 01451 Phone: 978-772-9295 Fax: 978-772-0140 |
Smilesuite Llc Dentist - Orthodontics and Dentofacial Orthopedics Medicare: Not Enrolled in Medicare Practice Location: 135 Prospect Hill Rd, Harvard, MA 01451 Phone: 781-710-7632 |
News Archive
Mylan's generic Doryx ANDA receives final FDA approval
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg. This product is the generic version of Mayne Pharma's Doryx, which is a tetracycline-class antimicrobial.
Bruker light-sheet microscopes at major comprehensive cancer center
Bruker Corporation (Nasdaq: BRKR), a leading supplier of single-plane illumination microscopy (SPIM) technology for research on live cells and cleared biological samples, today announced that two Luxendo MuVi™ and LCS SPIM™ light-sheet microscopes have been installed by Memorial Sloan Kettering Cancer Center (MSK).
An insight into caring for dementia in particular 'aggressive dementia'
By the age of 65 one out of every ten persons has some form of dementia, and by the age of 85 (the fastest growing segment of the population), one out of every two. Statistically families (and many doctors who are not dementia specialists) ignore the early warning signs because they incorrectly believe that the odd behaviors are just a normal part of aging and untreatable senility.
AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients
AstraZeneca today announced that the US Food and Drug Administration has approved TAGRISSO (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
› Verified 1 days ago